Cabergoline as treatment of ovarian hyperstimulation syndrome: A review

Gynecological Endocrinology

Volumn 29, Issue 2, 2013, Pages 98-100

  Kalampokas, Theodoros ^a   Creatsas, George ^a   Kalampokas, Emmanouil ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Cabergoline; Infertility; IVF; OHSS

Indexed keywords

CABERGOLINE;

CLINICAL PRACTICE; DRUG EFFICACY; EMOTIONALITY; FERTILIZATION IN VITRO; FINANCIAL MANAGEMENT; HOSPITALIZATION; HUMAN; LENGTH OF STAY; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; OVARY HYPERSTIMULATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SOCIAL ASPECT; SYSTEMATIC REVIEW (TOPIC);

CHORIONIC GONADOTROPIN; DOPAMINE AGONISTS; ERGOLINES; EVIDENCE-BASED MEDICINE; FEMALE; FERTILITY AGENTS, FEMALE; GENE EXPRESSION REGULATION; HUMANS; OVARIAN HYPERSTIMULATION SYNDROME; OVARY; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84871421157     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2012.730578     Document Type: Review

References (39)

1. Andersen AN, Gianaroli L, Felberbaum R, de Mouzon J, Nygren KG; European IVF-monitoring programme (EIM) for the European Society of Human Reproduction and Embryology (ESHRE). Assisted reproductive technology in Europe, 2002. Results generated from European registers by ESHRE. Hum Reprod 2006;21:1680-1697.
2. Mathur R, Kailasam C, Jenkins J. Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome. Hum Fertil (Camb) 2007;10:75-85. (Pubitemid 46964274)
3. Madill JJ, Mullen NB, Harrison BP. Ovarian hyperstimulation syndrome: a potentially fatal complication of early pregnancy. J Emerg Med 2008;35:283-286.
4. Mozes M, Bogokowsky H, Antebi E, Lunenfeld B, Rabau E, Serr DM, David A, Salomy M. Thromboembolic phenomena after ovarian stimulation with human gonadotrophins. Lancet 1965;2:1213-1215.
5. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002;8:559-577. (Pubitemid 35452781)
6. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008;89:84-91.
7. Mathur RS, Jenkins JM. Is ovarian hyperstimulation syndrome associated with a poor obstetric outcome? BJOG 2000;107:943-946. (Pubitemid 30495446)
8. Yan Z, Weich HA, Bernart W, Breckwoldt M, Neulen J. Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro. J Clin Endocrinol Metab 1993;77:1723-1725. (Pubitemid 24000942)
9. Rizk B, Aboulghar M, Smitz J, Ron-El R. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update 1997;3:255-266. (Pubitemid 27437930)
10. Enskog A, Nilsson L, Brännström M. Plasma levels of free vascular endothelial growth factor(165) (VEGF(165)) are not elevated during gonadotropin stimulation in in vitro fertilization (IVF) patients developing ovarian hyperstimulation syndrome (OHSS): results of a prospective cohort study with matched controls. Eur J Obstet Gynecol Reprod Biol 2001;96:196-201. (Pubitemid 32522560)
11. Soares SR, Gómez R, Simón C, García-Velasco JA, Pellicer A. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update 2008;14:321-333. (Pubitemid 351858972)
12. Gomez R, Soares SR, Busso C, Garzia-Velasco JA, Simon C, Pellicer A. Physiology and pathology of ovarian hyperstimulation syndrome: a systematic review and metaanalysis. Feril Steril 2011;95:188-196.
13. Ata B, Seyhan A, Orhaner S, Urman B. High dose cabergoline in management of ovarian hyperstimulation syndrome. Fertil Steril 2009;92:1168.e1-1168.e4.
14. Alvarez C, Alonso-Muriel I, García G, Crespo J, Bellver J, Simón C, Pellicer A. Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod 2007;22:3210-3214. (Pubitemid 351696781)
15. Papaleo E, Doldi N, De Santis L, Marelli G, Marsiglio E, Rofena S, Ferrari A. Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome. Hum Reprod 2001;16:2263-2266. (Pubitemid 33054119)
16. Manno M, Tomei F, Marchesan E, Adamo V. Cabergoline: a safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome? Eur J Obstet Gynecol Reprod Biol 2005;122:127-128. (Pubitemid 41265694)
17. Balasch J, Fábregues F, Arroyo V. Peripheral arterial vasodilation hypothesis: a new insight into the pathogenesis of ovarian hyperstimulation syndrome. Hum Reprod 1998;13:2718-2730. (Pubitemid 28482716)
18. Haning RV Jr, Austin CW, Carlson IH, Kuzma DL, Shapiro SS, Zweibel WJ. Plasma estradiol is superior to ultrasound and urinary estriol glucuronide as a predictor of ovarian hyperstimulation during induction of ovulation with menotropins. Fertil Steril 1983;40:31-36. (Pubitemid 13070179)
19. Asch RH, Li HP, Balmaceda JP, Weckstein LN, Stone SC. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Hum Reprod 1991;6:1395-1399.
20. Rizk B. Ovarian hyperstimulation syndrome-epidemiology, pathophysiology, prevention and management, 1st edn. New York: Cambridge University Press, 2006, pp. 10-33.
21. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22. (Pubitemid 29038270)
22. Olson TA, Mohanraj D, Carson LF, Ramakrishnan S. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 1994;54:276-280. (Pubitemid 24042123)
23. Gómez R, Simón C, Remohí J, Pellicer A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology 2002;143:4339-4348. (Pubitemid 35239566)
24. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992;255:989-991.
25. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994;269:26988-26995. (Pubitemid 24332901)
26. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995;376:62-66.
27. McClure N, Healy DL, Rogers PA, Sullivan J, Beaton L, Haning RV Jr, Connolly DT, Robertson DM. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994;344:235-236. (Pubitemid 24229013)
28. Glade-Bender J, Kandel JJ, Yamashiro DJ. VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther 2003;3:263-276. (Pubitemid 36458758)
29. Kuenen BC, Tabernero J, Baselga J, Cavalli F, Pfanner E, Conte PF, Seeber S, et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res 2003;9:1648-1655. (Pubitemid 36554587)
30. Sarkar C, Chakroborty D, Mitra RB, Banerjee S, Dasgupta PS, Basu S. Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells. Am J Physiol Heart Circ Physiol 2004;287:H1554-H1560. (Pubitemid 39313259)
31. Alvarez C, Martí-Bonmatí L, Novella-Maestre E, Sanz R, Gómez R, Fernández-Sánchez M, Simón C, Pellicer A. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007;92:2931-2937. (Pubitemid 47236352)
32. Carizza C, Abdelmassih V, Abdelmassih S, Ravizzini P, Salgueiro L, Salgueiro PT, Jine LT, et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online 2008;17:751-755.
33. Youssef MA, van Wely M, Hassan MA, Al-Inany HG, Mochtar M, Khattab S, van der Veen F. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Hum Reprod Update 2010;16:459-466.
34. Tehraninejad ES, Hafezi M, Arabipoor A, Aziminekoo E, Chehrazi M, Bahmanabadi A. Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. J Assist Reprod Genet 2012;29:259-264.
35. Shaltout A, Shohayeb A, Eid M, Abbas S. Role of cabergoline in preventing ovarian hyperstimlation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Abstracts of the 25th Annual Meeting of ESHRE, Amsterdam, The Netherlands, 28 June-1 July 2009.
36. Novella-Maestre E, Carda C, Noguera I, Ruiz-Saurí A, García-Velasco JA, Simón C, Pellicer A. Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis. Hum Reprod 2009;24:1025-1035.
37. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356:29-38. (Pubitemid 46041751)
38. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39-46. (Pubitemid 46041752)
39. Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf) 2009;70:104-108.